Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.55 ▲ +0.09
(+20.82%)
MKT CAP: $3.7M • VOL: 6.41M
52W L $0 52W H $32
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
CRIS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.4M | $10.9M | $10.0M |
| YoY Revenue Growth % | -13.4% | +8.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.7M | -$44.5M | -$48.3M |
| Operating Margin % | -60.5% | -80.0% | -80.0% |
| Net Income (GAAP) | -$7.6M | -$43.4M | -$47.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.2M | -$39.6M | -$38.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$27.2M | -$39.6M | -$38.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.1M | $20.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.5M | -$6.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRIS.